News

FDA approves twice-a-year injection for HIV prevention
A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...
Lenacapavir HIV shot approved in US may enter Canada by 2026; just two injections needed a year
A twice-yearly injectable drug, lenacapavir, hailed as a breakthrough in HIV prevention, could be available in Canada by ...
US approves twice-yearly injection for HIV prevention. What you need to know about lenacapavir
The US Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that offers long-lasting protection ...
HIV prevention drug lenacapavir approved by FDA as twice-yearly injection
Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...
The FDA Just Approved a Long-Lasting Injection to Prevent HIV
Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...
Public Broadcasting Service (PBS)4d
6 things to know about lenacapavir, what experts call a ‘wonder drug’ for preventing HIV
The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...
KUNC1d
FDA approves HIV medication Lenacapavir, but it's costly
A newly approved HIV medication provides near-total protection against infection with just two injections a year. It's called Lenacapavir. But the high price of the drug could limit its reach.
Healthline2d
FDA Approves 'Breakthrough' Twice-Yearly Injection to Prevent HIV
The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence ...
FDA approves new twice-yearly HIV shot. What to know
The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...
Metro Weekly3d
FDA Approves PrEP Drug Requiring Only Two Injections Per Year
Like other PrEP drugs, if enough of the medication is present when a person is exposed to HIV, it can prevent the virus from ...
MPR2d
Twice-Yearly HIV-1 PrEP Yeztugo Gets FDA Approval
Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.
Wall Street Journal1d
Gilead’s HIV Breakthrough - WSJ
Gilead tested lenacapavir—which was approved by the FDA in 2022 as a treatment for patients with drug-resistant HIV—in two clinical trials against its daily prophylactic pills.